

S1 Table. Baseline characteristics of patient groups according to palbociclib dose scheme

	Total (n=302)	Group 1 (n=174)	Group 2 (n=128)	p-value
Age (yr), median (range)	54 (28-84)	54 (28-83)	53 (29-84)	0.9060 ^{a)}
< 55	163 (54.0)	91 (52.3)	72 (56.3)	0.496
≥ 55	139 (46.0)	83 (47.7)	56 (43.7)	
Sex				
Female	302 (100)	174 (100)	128 (100)	
Disease status				
<i>De novo</i> stage IV	94 (31.1)	61 (35.1)	33 (25.8)	0.0853
Recurrent	208 (68.9)	113 (64.9)	95 (74.2)	
Visceral metastasis				
No	130 (43.1)	77 (44.3)	53 (41.4)	0.6215
Yes	172 (56.9)	97 (55.7)	75 (58.6)	
Bone-only disease				
No	230 (76.2)	142 (81.6)	88 (68.8)	0.0096
Yes	72 (28.8)	32 (18.4)	40 (31.2)	
Metastatic sites				
Lung	116 (38.4)	67 (38.5)	49 (38.3)	0.9684
Liver	47 (15.6)	22 (12.6)	25 (19.5)	0.1028
Brain	6 (2.0)	4 (2.3)	2 (1.6)	1.000 ^{b)}
Bone	169 (56.0)	88 (50.6)	81 (63.3)	0.0279
Distant lymph node	127 (42.1)	63 (36.2)	64 (50.0)	0.0164
Pleura	38 (12.6)	22 (12.6)	16 (12.5)	0.9703
Breast/Skin	10 (3.3)	5 (2.9)	5 (3.9)	0.7481 ^{b)}
Other	37 (12.3)	22 (12.6)	15 (11.7)	0.8086
No. of sites				
1	147 (48.7)	95 (54.6)	52 (40.6)	0.0615
2	85 (28.2)	42 (24.1)	43 (33.6)	
3	37 (12.3)	22 (12.6)	15 (11.7)	
4	33 (10.9)	15 (8.6)	18 (14.1)	

Values are presented as number (%) unless otherwise indicated. ^{a)}Kruskal-Wallis test, ^{b)}Fisher's exact test.